# Study of Pembrolizumab and Radiotherapy in Liver Cancer

> **NCT03316872** · PHASE2 · TERMINATED · sponsor: **University Health Network, Toronto** · enrollment: 18 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Stereotactic Body Radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT03316872
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-15
- **Primary completion:** 2024-02-15
- **Final completion:** 2024-02-15
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** The study was stopped due to the shift in systemic treatment paradigm for HCC precluding further enrolment.
- **Last updated:** 2025-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03316872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03316872, "Study of Pembrolizumab and Radiotherapy in Liver Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03316872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*